Patent intelligence · US
US 11168310
Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathy
Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathy
Patent details — US 11168310
- Jurisdiction
- US
- Status
- granted
- Grant date
- Nov 9, 2021
- Expiration
- Nov 4, 2041
- Applicant
- Entrada Therapeutics, Inc.
- Claims
- 35
- CPC classes
- A61K, A61K35/12, A61K38/45, A61K47/60
Quick answer
US 11168310 (Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathy) is held by Entrada Therapeutics, Inc.. Status: granted. Granted Nov 9, 2021. Expires Nov 4, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Entrada Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 35
- CPC classes
- A61K, A61K35/12, A61K38/45, A61K47/60, A61K47/645
More from Entrada Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 11987821
Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathy
granted -
US 11225506
Cell penetrating peptides and methods of making and using thereof
granted -
US 10815276
Cell penetrating peptides and methods of making and using thereof
granted -
US 10626147
Cell penetrating peptides and methods of making and using thereof
granted
Frequently asked questions
What is US patent 11168310?
US 11168310 (Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathy) is held by Entrada Therapeutics, Inc.. Status: granted. Granted Nov 9, 2021. Expires Nov 4, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11168310?
Entrada Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 5 pharmaceutical patents for this assignee.
When does US 11168310 expire?
Our index shows an expiration date of Nov 4, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.